Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Omalizumab exposure patterns in real-life: An 11-year French population-based study of 19,203 patients with severe asthma

Marc Humbert, Arnaud Bourdin, Antoine Deschildre, Mathieu Molimard, Camille Taille, Driss Kamar, Céline Thonnelier, Audrey Lajoinie, Alexandre Rigault
European Respiratory Journal 2021 58: PA3731; DOI: 10.1183/13993003.congress-2021.PA3731
Marc Humbert
1Université Paris-Saclay, Hôpital Bicêtre, Service de Pneumologie, Le Kremlin-Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mjc.humbert@gmail.com
Arnaud Bourdin
2University of Montpellier, INSERM U1046, CNRS UMR 9214, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France. Hôpital Arnaud-de-Villeneuve, Montpellier, Montpellier, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoine Deschildre
3Univ. Lille, CHU Lille, Pediatric Pulmonology and Allergy Department, Hôpital Jeanne de Flandre, Lille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathieu Molimard
4Service de Pharmacologie Médicale, CHU de Bordeaux-Université de Bordeaux-INSERM CR1219, Bordeaux, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Camille Taille
5Service de pneumologie et Centre de Référence-C des Maladies Pulmonaires rares, Hôpital Bichat, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Driss Kamar
6Novartis, Rueil Malmais, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Céline Thonnelier
7Novartis, Rueil Malmaison, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Audrey Lajoinie
8RCTs, Lyon, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandre Rigault
8RCTs, Lyon, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: The real-life effectiveness of omalizumab (OMA) has been widely studied since it was commercialized 15 years ago but exposure patterns and factors of persistence remain to be explored, particularly in children.

Aims and objectives: To describe patient characteristics and treatment exposure patterns of patients initiating OMA for severe asthma in France, and factors associated with persistence before long-term discontinuation (≥1 year).

Methods: The French administrative healthcare database (SNDS) was used to identify asthma patients aged ≥6 years who were prescribed OMA for at least 16 weeks from Jan 2009-Dec 2019. We examined OMA treatment patterns using Continuous Measures for Medication Acquisition (CMA), Kaplan-Meier, and Cox models (stepwise analysis).

Results: We identified 19,203 OMA initiations during the study period: 2,453 children and 16,750 adults. The mean [SD] age was 47.7 [19.9] years and 59.0% were female. Around 50% of the adults discontinued OMA before 54 months, with a Medication Possession Ratio of 93.4 [11.0] %. The probability of persistence at 2 years was 0.66 [95%CI: 0.65;0.67]. Trends observed in children were similar. Persistence in adults was associated with year of initiation and age, comorbidity of interest and use of antihistamines. In children, persistence was associated with a history of hospitalization for exacerbation, cumulative dose of oral corticosteroids, and use of antihistamines.

Conclusion: This French population study in 19,203 patients describes a long-term persistence of OMA treatment and highlights factors associated to its persistance.

  • Treatments
  • Asthma - management
  • Pharmacology

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3731.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Omalizumab exposure patterns in real-life: An 11-year French population-based study of 19,203 patients with severe asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Omalizumab exposure patterns in real-life: An 11-year French population-based study of 19,203 patients with severe asthma
Marc Humbert, Arnaud Bourdin, Antoine Deschildre, Mathieu Molimard, Camille Taille, Driss Kamar, Céline Thonnelier, Audrey Lajoinie, Alexandre Rigault
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3731; DOI: 10.1183/13993003.congress-2021.PA3731

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Omalizumab exposure patterns in real-life: An 11-year French population-based study of 19,203 patients with severe asthma
Marc Humbert, Arnaud Bourdin, Antoine Deschildre, Mathieu Molimard, Camille Taille, Driss Kamar, Céline Thonnelier, Audrey Lajoinie, Alexandre Rigault
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3731; DOI: 10.1183/13993003.congress-2021.PA3731
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Impact of biologic therapy in severe asthma with nasal polyps
  • Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma
  • Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab
Show more Airway pharmacology and treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society